Table 2.
SOC, PT | 0.4 mg/kg (N = 6) | 0.6 mg/kg (N = 6) | 0.9 mg/kg (N = 6) | |||
---|---|---|---|---|---|---|
|
|
|
||||
Number of subjects (%) | Number of events | Number of subjects (%) | Number of events | Number of subjects (%) | Number of events | |
Total | 5 (83.3) | 13 | 5 (83.3) | 7 | 5 (83.3) | 21 |
Nervous system disorders | 2 (33.3) | 2 | 2 (33.3) | 2 | 5 (83.3) | 5 |
Abnormal limb movements | 2 (33.3) | 2 | 2 (33.3) | 2 | 5 (83.3) | 5 |
Cardiac disorders | 4 (66.7) | 5 | 2 (33.3) | 2 | 2 (33.3) | 2 |
Sinus bradycardia | 4 (66.7) | 4 | 2 (33.3) | 2 | 2 (33.3) | 2 |
Atrioventricular block | 1 (16.7) | 1 | 0 (0) | 0 | 0 (0) | 0 |
Investigations | 1 (16.7) | 4 | 1 (16.7) | 1 | 4 (66.7) | 7 |
Prolonged QT interval | 1 (16.7) | 4 | 1 (16.7) | 1 | 3 (50.0) | 6 |
Elevated urobilinogen | 0 (0) | 0 | 0 (0) | 0 | 1 (16.7) | 1 |
Gastrointestinal disorders | 0 (0) | 0 | 1 (16.7) | 1 | 2 (33.3) | 2 |
Thirst | 0 (0) | 0 | 0 (0) | 0 | 1 (16.7) | 1 |
Canker sore | 0 (0) | 0 | 1 (16.7) | 1 | 1 (16.7) | 1 |
General disorders and administration site conditions | 1 (16.7) | 1 | 0 (0) | 0 | 2 (33.3) | 2 |
Medical devices related pain | 1 (16.7) | 1 | 0 (0) | 0 | 2 (33.3) | 2 |
Infections and infestations | 0 (0) | 0 | 0 (0) | 0 | 1 (16.7) | 1 |
Influenza | 0 (0) | 0 | 0 (0) | 0 | 1 (16.7) | 1 |
Musculoskeletal and connective tissue disorders | 1 (16.7) | 1 | 0 (0) | 0 | 0 (0) | 0 |
Musculoskeletal discomfort | 1 (16.7) | 1 | 0 (0) | 0 | 0 (0) | 0 |
Psychiatric disorders | 0 (0) | 0 | 0 (0) | 0 | 1 (16.7) | 1 |
Dysphoria | 0 (0) | 0 | 0 (0) | 0 | 1 (16.7) | 1 |
Vascular disorders | 0 (0) | 0 | 1 (16.7) | 1 | 0 (0) | 0 |
Hypotension | 0 (0) | 0 | 1 (16.7) | 1 | 0 (0) | 0 |
Eye disorders | 0 (0) | 0 | 0 (0) | 0 | 1 (16.7) | 1 |
Blurred vision | 0 (0) | 0 | 0 (0) | 0 | 1 (16.7) | 1 |
Note: PT, preferred terms; SOC, systematic organ classification.